Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan 75 mg versus 10 mg in symptomatic pulmonary arterial hypertension
NL-OMON54353Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of macitentan in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Time to first CEC-adjudicated morbidity or mortality event. Started Dec 2021; status: recruiting.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON54353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54353.